Research at Oslo University Hospital basis for international drug development initiative between Norway and India
SERCA Pharmaceuticals AS, a company established by Inven2 AS in October, recently entered a co-development agreement with Cadila Pharmaceuticals - an FDA-approved Indian Pharma company with some 6000 employees. SERCA Pharmaceuticals AS is established based on a drug development and innovation project on ischemia reperfusion injury in myocardial infarction that has been going on in the groups of Professors Kjetil Tasken (formerly NCMM UiO/OUH, now ICR, OUH) and Ivar Sjaastad (IEMF, OUH). The researchers have taken this forward to a drug candidate and have documented effects biochemically, in heart cells, by electrophysiology, on normal rat hearts and in rats with ischemia reperfusion injury where there is a cardioprotective effect.
The work has involved Birgitte Lygren (former postdoc), Ellen Østensen (PhD 2016), Ana Calejo (former postdoc and now researcher with UiO SPARK grant) in the Taskén group at UiO/OUH and has been done in collaboration with Professor Jo Klaveness at Institute of Pharmacy and Professor Ivar Sjaastad and Researcher Jan Magnus Aaronsen at Institute of Experimental Medical Research at Oslo University Hospital and in collaboration with Inven2, particularly Mohammed Amarzguioui and Kristin Sandereid, that have been involved in the technology and business development and led to the establishment of SERCA Pharmaceuticals AS.
SERCA Pharmaceuticals AS has won a 5-mill NOK Forny grant from RCN. The agreement with Cadila will take the project forward and provides a real chance to go into humans with planned phase 1 and 2 studies.
Inven2's most recent startup company, Serca Pharmaceuticals, signed a development agreement with Cadila Pharmaceuticals in New Delhi today. The signing was overseen by Prime Minister of Norway, Erna Solberg, during her official visit to India. Serca Pharmaceuticals is based on breakthrough science from Kjetil Taskéns Group at the University of Oslo. Read more
Published in major journals, first or last author from Oslo University Hospital.
Hamfjord J, Guren T, Dajani O, Glimelius B, Sorbye H, Pfeiffer P, Christoffersen T, Lingjærde O, Tveit K, Kure E, Pallisgaard N, Spindler K(2018) Total circulating cell-free DNA (cfDNA) as a prognostic biomarker in metastatic colorectal cancer prior to first-line oxaliplatin-based chemotherapy Ann Oncol, 29 Suppl 5, v109 DOI 10.1093/annonc/mdy149.025, PubMed 32177006
Skotland T, Sagini K, Sandvig K, Llorente A(2020) An emerging focus on lipids in extracellular vesicles Adv Drug Deliv Rev(in press) DOI 10.1016/j.addr.2020.03.002, PubMed 32151658
Skjerven HO, Rehbinder EM, Vettukattil R, LeBlanc M, Granum B, Haugen G, Hedlin G, Landrø L, Marsland BJ, Rudi K, Sjøborg KD, Söderhäll C, Staff AC, Carlsen KH, Asarnoj A, Bains KES, Carlsen OCL, Endre KMA, Granlund PA, Hermansen JU, Gudmundsdóttir HK, Hilde K, Håland G, Kreyberg I, Olsen ICet al.(2020) Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial Lancet, 395(10228), 951-961 DOI 10.1016/S0140-6736(19)32983-6, PubMed 32087121